ArticleBMJ open2026
Safety and efficacy of metformin for the treatment of pain: protocol for a systematic review.
Article in BMJ open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPain remains difficult to manage due to limited efficacy and adverse effects of many existing analgesics, highlighting the need for safer non-opioid treatment strategies. Metformin is a widely prescribed oral antihyperglycaemic agent with emerging preclinical and early clinical evidence suggesting potential analgesic effects. Proposed mechanisms include activation of AMP-activated protein kinase with downstream inhibition of mammalian target of rapamycin and mitogen-activated protein kinase signalling pathways implicated in nociceptive sensitisation and chronic pain. This protocol describes a systematic review to evaluate the efficacy and safety of metformin for the treatment or prevention of pain in an adult population. METHODS AND ANALYSIS: This systematic review will include randomised, double-blind, placebo or active-controlled trials evaluating orally administered metformin for the treatment or prevention of acute or chronic pain in adult human participants. Searches will be conducted in MEDLINE (Ovid MEDLINE ALL), EMBASE and the Cochrane Central Register of Controlled Trials from inception alongside ClinicalTrials.gov, the WHO International Clinical Trials Registry Platform and reference list screening. Two reviewers will independently screen studies, extract data and assess risk of bias using the Cochrane Risk of Bias 2.0 tool. Outcomes will include pain intensity, pain relief, responder outcomes, functional interference, analgesic use and adverse events. Where appropriate, random-effects meta-analyses will be performed. Certainty of evidence will be evaluated using the Grading of Recommendations Assessment, Development and Evaluation approach. ETHICS AND DISSEMINATION: Ethics approval is not required as this study will synthesise published data. Findings will be disseminated through peer-reviewed publication and presentation in scientific conferences. PROSPERO REGISTRATION NUMBER: CRD420261296816.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.